Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa.

Thomi, R; Yerly, Daniel; Yawalkar, Nikhil; Simon, Dagmar; Schlapbach, Christoph; Hunger, Robert (2017). Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa. British journal of dermatology, 177(5), pp. 1358-1366. Wiley-Blackwell 10.1111/bjd.15458

[img] Text
Thomi_et_al-2017-British_Journal_of_Dermatology.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (897kB) | Request a copy
[img]
Preview
Text
IL-32 revision.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (237kB) | Preview

BACKGROUND Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Its immunopathogenic mechanisms are still poorly understood. Previous studies demonstrated that the proinflammatory cytokine interleukin (IL)-32 is implicated in the pathogenesis of other inflammatory diseases. OBJECTIVES To investigate the tissue expression and systemic levels of IL-32, as well as its cellular sources, in patients with HS in comparison with healthy donors and patients with two other inflammatory skin diseases: psoriasis and atopic dermatitis (AD). METHODS Tissue samples were obtained from healthy skin and lesional HS, psoriatic and AD skin to analyse the expression of IL-32 by immunohistochemistry and semiquantitative real-time polymerase chain reaction. The cellular source of the cytokine was determined by double immunofluorescence staining. Serum from the four donor groups was used to measure systemic levels of IL-32 by enzyme-linked immunosorbent assay. RESULTS IL-32 was upregulated in patients with HS in both lesional skin and serum when compared with healthy donors and patients with AD or psoriasis. In HS, IL-32 was found to be expressed by natural killer cells, T cells, macrophages and dendritic cells in highly infiltrated areas of the dermis. High IL32 mRNA levels in lesional HS skin coincided with high amounts of T cells and macrophages. Additionally, IL32 mRNA levels in lesional HS skin correlate positively with interferon-γ and IL-17A and negatively with IL-13. CONCLUSIONS Our findings suggest that IL-32 is overexpressed in HS. Targeting IL-32 may therefore represent a new therapeutic option for the treatment of this recalcitrant disease.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Yerly, Daniel; Yawalkar, Nikhil; Simon, Dagmar; Schlapbach, Christoph and Hunger, Robert

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0007-0963

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

19 Feb 2018 16:28

Last Modified:

01 Dec 2018 02:30

Publisher DOI:

10.1111/bjd.15458

PubMed ID:

28301691

BORIS DOI:

10.7892/boris.110244

URI:

https://boris.unibe.ch/id/eprint/110244

Actions (login required)

Edit item Edit item
Provide Feedback